Back to JPMORGAN CHASE & CO JPMORGAN CHASE & CO

KTTAKTTA
8 quarters

Position history for JPMORGAN CHASE & COJPMORGAN CHASE & CO's holdings in PASITHEA THERAPEUTICS CORP

Yes. JPMorgan Chase holds 150 shares of KTTA (Pasithea Therapeutics), worth $79, as of its Q2 2026 13F filing. The share count is unchanged from Q1 2026. JPMorgan Chase has held KTTA in every 13F on record since Q3 2024, 8 quarterly filings.

Current Value

$79

Current Shares

150

Total Value Change

-$734

Total Shares Change

0

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Unchanged
150
0.0%
$790.0%$0.52
0
2026-Q1
Unchanged
150
0.0%
$1070.0%$0.74
0
2025-Q4
Unchanged
150
0.0%
$1940.0%$1.29
0
2025-Q3
Unchanged
150
0.0%
$1080.0%$0.73
0
2025-Q2
Unchanged
150
0.0%
$1080.0%$0.72
0
2025-Q1
Unchanged
150
0.0%
$1950.0%$1.30
0
2024-Q4
Unchanged
150
0.0%
$4730.0%$3.15
0
2024-Q3
First report
150
-
$8130.0%$5.42
0

Other major holders of KTTA: Janus Henderson Group Ltd., ADAGE CAPITAL PARTNERS GP, L.L.C., AMERIPRISE FINANCIAL INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used